Xtant Medical Holdings, Inc. (XTNT) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-13

Key Insights

Xtant Medical has entered into an exclusive distribution agreement with Dilon Technologies to import, market, and sell Dilon's HEMOBLAST® Bellows product in the United States. This agreement provides Xtant with an opportunity to expand its product portfolio and potentially generate additional revenue.
Xtant has hired approximately 20 Dilon sales personnel to assist in the sale of the HEMOBLAST® Bellows product, which indicates the company is investing resources to support the successful launch and distribution of the product.
The distribution agreement includes a $5.0 million exclusivity fee paid by Xtant to Dilon, which can be subject to repayment under certain circumstances, including upon termination of the agreement. This suggests a significant financial commitment by Xtant to secure the exclusive distribution rights.

Want the newest filings?

This analysis covers the filing from 2026-04-13. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-01-16

Xtant Medical completed the sale of its Coflex and CoFix product lines to Companion Spine for $17.5 million, with $8.2 million received in the form of a promissory note.
The company also completed the sale of its subsidiary Paradigm Spine GmbH to Companion Spine for $1.7 million, with a potential purchase price adjustment.
The maturity date of the $8.2 million promissory note and the timing of the purchase price adjustment for the Paradigm Spine GmbH sale have been extended to January 31, 2026.

Other reports for Xtant Medical Holdings, Inc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.